-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis announced that its highly selective Bruton tyrosine kinase inhibitor Rhapsido® has been approved by the US FDA to treat symptomatic skin blemishes in adults who are unable to fully control symptoms after H1 antihistamines. This is also a new indication that the drug expanded after chronic spontaneous urticaria.

Zhitongcaijing·10/07/2026 15:57:03
Listen to the news
Novartis announced that its highly selective Bruton tyrosine kinase inhibitor Rhapsido® has been approved by the US FDA to treat symptomatic skin blemishes in adults who are unable to fully control symptoms after H1 antihistamines. This is also a new indication that the drug expanded after chronic spontaneous urticaria.